Donald E. Coling, Ph.D.
The Research
Proteomic investigation of cisplatin-induced ototoxicity
Cisplatin is one of the most frequently used chemotherapeutic agents. However, side effects of hearing loss and kidney failure limits its clinical use. More than 50 percent of patients treated with cisplatin suffer cochlear hair cell death. Identification of proteins whose degradation or synthesis is induced by cisplatin is expected to lead to new methods of clinical intervention to reduce negative side effects.